Background & aims: Advances in development of therapeutic agents for ulcerative colitis (UC) have been paralleled by innovations in trial design. It would be useful to identify a core outcome set, to standardize outcome definitions for efficacy and safety in clinical trials. We performed a systematic review of efficacy and safety outcomes reported in placebo-controlled randomized controlled trials of patients with UC.


Adverse Effects, COS, Gastrointestinal Agents, IBD, MCS, Pathology, RCT, therapeutic use, Therapy, Treatment Outcome, UCDAI, Ulcerative Colitis

Read More